AxoGen is a biotech company developing treatment options for the reconstruction and repair of peripheral nerve injuries. It is passionate about restoring nerve function and quality of life to patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body.
AxoGen's portfolio of products includes Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves, AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments and Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that may be used as a soft tissue covering to reduce inflammation and scar tissue formation. 

Alachua, US
Size (employees)
114 (est)+41%
AxoGen was founded in 2002 and is headquartered in Alachua, US

Key People at AxoGen

Karen Zaderej

Karen Zaderej

Gregory G. Freitag

Gregory G. Freitag

General Counsel, SVP Business Development, Director

AxoGen Office Locations

AxoGen has an office in Alachua
Alachua, US (HQ)
13631 Progress Blvd

AxoGen Data and Metrics

AxoGen Financial Metrics

AxoGen's revenue was reported to be $41.1 m in FY, 2016 which is a 50% increase from the previous period.

Revenue (FY, 2016)

41.1 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

34.6 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

(14.4 m)

EBIT (FY, 2016)

(8.1 m)

Market capitalization (27-Jun-2017)

496.4 m

Closing share price (27-Jun-2017)


Cash (31-Dec-2016)

30 m
AxoGen's current market capitalization is $496.4 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


10.9 m16.8 m27.3 m41.1 m

Revenue growth, %


Cost of goods sold

2.4 m3.4 m4.8 m6.5 m

Gross profit

8.5 m13.4 m22.5 m34.6 m

Gross profit Margin, %


Operating expense total

15.7 m19.7 m26.9 m42.8 m


(9.6 m)(9.8 m)(9.3 m)(8.1 m)

EBIT margin, %


Interest expense

(4.8 m)(6.8 m)(4 m)(5.4 m)

Pre tax profit

(14.6 m)

Net Income

(14.6 m)(17.7 m)(13.4 m)(14.4 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016


20.1 m8.2 m25.9 m30 m


3.4 m3.2 m3.9 m5.5 m

Current Assets

25.7 m14.4 m35.1 m44 m


381.7 k619 k970.9 k1.5 m

Total Assets

27.7 m16.4 m37.5 m46.4 m

Accounts Payable

2.1 m2.4 m3.7 m7 m

Current Liabilities

2.1 m2.4 m3.7 m11.1 m

Additional Paid-in Capital

72.4 m78.7 m111.4 m132.5 m

Retained Earnings

(72.4 m)(90.1 m)(103.5 m)(117.9 m)

Total Equity

136.6 k(11.2 m)8.2 m14.9 m

Financial Leverage

202.6 x-1.5 x4.6 x3.1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(14.6 m)(17.7 m)(13.4 m)(14.4 m)

Depreciation and Amortization

138.3 k198.9 k249 k

Accounts Receivable

(902.2 k)(1 m)(2 m)


(247.3 k)184.8 k(720.3 k)5.5 m

Accounts Payable

430.6 k498.3 k1.1 m7 m

Cash From Operating Activities

(10.4 m)(10.5 m)(13.1 m)

Purchases of PP&E

(178.8 k)(542 k)(408.8 k)

Cash From Investing Activities

(244 k)(594 k)(555.5 k)

Long-term Borrowings

(1.8 m)(1.8 m)

Cash From Financing Activities

16.9 m31.3 m

Interest Paid

1 m3.9 m3.5 m
USDY, 2016


360.6 k

Financial Leverage

3.1 x

AxoGen Market Value History

AxoGen Job Categories

AxoGen Online and Social Media Presence

AxoGen Company Life and Culture

You may also be interested in